Cargando…

Real world costs and cost-effectiveness of Rituximab for diffuse large B-cell lymphoma patients: a population-based analysis

BACKGROUND: Current treatment of diffuse-large-B-cell lymphoma (DLBCL) includes rituximab, an expensive drug, combined with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy. Economic models have predicted rituximab plus CHOP (RCHOP) to be a cost-effective alternative to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Khor, Sara, Beca, Jaclyn, Krahn, Murray, Hodgson, David, Lee, Linda, Crump, Michael, Bremner, Karen E, Luo, Jin, Mamdani, Muhammad, Bell, Chaim M, Sawka, Carol, Gavura, Scott, Sullivan, Terrence, Trudeau, Maureen, Peacock, Stuart, Hoch, Jeffrey S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4148552/ https://www.ncbi.nlm.nih.gov/pubmed/25117912 http://dx.doi.org/10.1186/1471-2407-14-586

Ejemplares similares

Differences in Incremental Cost-Effectiveness Ratios for Common Versus Rare Conditions: A Case from Oncology
por: Jayasundara, Kavisha, et al.
Publicado: (2017)

Estimating the clinical cost of drug development for orphan versus non-orphan drugs
por: Jayasundara, Kavisha, et al.
Publicado: (2019)

Phase-specific and lifetime costs of cancer care in Ontario, Canada
por: de Oliveira, Claire, et al.
Publicado: (2016)

Estimating the Cost of Cancer Care in British Columbia and Ontario: A Canadian Inter-Provincial Comparison
por: De Oliveira, Claire, et al.
Publicado: (2017)

Real-World Cost-Effectiveness of Bevacizumab With First-Line Combination Chemotherapy in Patients With Metastatic Colorectal Cancer: Population-Based Retrospective Cohort Studies in Three Canadian Provinces
por: Pataky, Reka E., et al.
Publicado: (2021)

Comparing Childhood Cancer Care Costs in Two Canadian Provinces
por: McBride, Mary L., et al.
Publicado: (2020)

The effectiveness of rituximab and HIV on the survival of Ontario patients with diffuse large B‐cell lymphoma
por: Habbous, Steven, et al.
Publicado: (2020)

Cost‐effectiveness of second‐line ipilimumab for metastatic melanoma: A real‐world population‐based cohort study of resource utilization
por: Lu, Brandon, et al.
Publicado: (2023)

Real-World Cost-Effectiveness of First-Line Gemcitabine Plus Nab-Paclitaxel vs FOLFIRINOX in Patients With Advanced Pancreatic Cancer
por: Arciero, Vanessa, et al.
Publicado: (2022)

Increasing Operational Capacity and Reducing Costs of Rituximab Administration: A Costing Analysis
por: Wallace, Zachary S., et al.
Publicado: (2020)

Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration
por: Chan, Kelvin, et al.
Publicado: (2020)

Methodological Issues in Economic Evaluations Submitted to the Pan-Canadian Oncology Drug Review (pCODR)
por: Masucci, Lisa, et al.
Publicado: (2017)

Developing the Breast Utility Instrument, a preference-based instrument to measure health-related quality of life in women with breast cancer: Confirmatory factor analysis of the EORTC QLQ-C30 and BR45 to establish dimensions
por: Tsui, Teresa C. O., et al.
Publicado: (2022)

“Bring the Hoses to Where the Fire Is!”: Differential Impacts of Marginalization and Socioeconomic Status on COVID-19 Case Counts and Healthcare Costs
por: Cheung, Douglas C., et al.
Publicado: (2022)

The Opportunity Cost of Capital: Development of New Pharmaceuticals
por: Chit, Ayman, et al.
Publicado: (2015)

Comparison of Use of Neoadjuvant Systemic Treatment for Breast Cancer and Short-term Outcomes Before vs During the COVID-19 Era in Ontario, Canada
por: Habbous, Steven, et al.
Publicado: (2022)

Improving chronic disease prevention and screening in primary care: results of the BETTER pragmatic cluster randomized controlled trial
por: Grunfeld, Eva, et al.
Publicado: (2013)

Health care costs associated with hepatitis C virus infection in First Nations populations in Ontario: a retrospective matched cohort study
por: Mendlowitz, Andrew, et al.
Publicado: (2021)

Lenalidomide plus rituximab Vs rituximab alone in relapsed or refractory indolent lymphoma: A cost‐effectiveness analysis
por: Zhang, Peng‐Fei, et al.
Publicado: (2020)

Comparative Cost Analysis Of Intravenous And Subcutaneous Administration Of Rituximab In Lymphoma Patients
por: Delgado Sánchez, Olga, et al.
Publicado: (2019)

Health care costs associated with chronic hepatitis C virus infection in Ontario, Canada: a retrospective cohort study
por: Wong, William W.L., et al.
Publicado: (2021)

Regional variation in cost of neonatal intensive care for extremely preterm infants
por: Rolnitsky, Asaph, et al.
Publicado: (2021)

Cost of neonatal intensive care for extremely preterm infants in Canada
por: Rolnitsky, Asaph, et al.
Publicado: (2021)

The impact of pricing strategy on the costs of oral anti‐cancer drugs
por: Truong, Judy, et al.
Publicado: (2019)

The impact of the early COVID-19 pandemic on healthcare system resource use and costs in two provinces in Canada: An interrupted time series analysis
por: Zeitouny, Seraphine, et al.
Publicado: (2023)

Using the net benefit regression framework to construct cost-effectiveness acceptability curves: an example using data from a trial of external loop recorders versus Holter monitoring for ambulatory monitoring of "community acquired" syncope
por: Hoch, Jeffrey S, et al.
Publicado: (2006)

Initial health care costs for COVID-19 in British Columbia and Ontario, Canada: an interprovincial population-based cohort study
por: Tsui, Teresa C.O., et al.
Publicado: (2022)

Cost-effectiveness of obinutuzumab versus rituximab biosimilars for previously untreated follicular lymphoma
por: Spencer, Scott J, et al.
Publicado: (2021)

Cost-effectiveness analysis of first-line treatment with crizotinib in ROS1-rearranged advanced non-small cell lung cancer (NSCLC) in Canada
por: Beca, Jaclyn M., et al.
Publicado: (2021)

The price of neonatal intensive care outcomes – in-hospital costs of morbidities related to preterm birth
por: Rolnitsky, Asaph, et al.
Publicado: (2023)

Development of a Multi-Criteria Decision Analysis Rating Tool to Prioritize Real-World Evidence Questions for the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration
por: Parmar, Ambica, et al.
Publicado: (2023)

Does it Matter Whether Canada’s Separate Health Technology Assessment Process for Cancer Drugs has an Economic Rationale?
por: Hoch, Jeffrey S., et al.
Publicado: (2015)

Techniques for estimating health care costs with censored data: an overview for the health services researcher
por: Wijeysundera, Harindra C, et al.
Publicado: (2012)

Copanlisib plus rituximab combination therapy vs. rituximab monotherapy for relapsed indolent non-Hodgkin lymphoma: a cost-effectiveness analysis
por: Tang, Xiao, et al.
Publicado: (2022)

Developing the Breast Utility Instrument to Measure Health-Related Quality-of-Life Preferences in Patients with Breast Cancer: Selecting the Item for Each Dimension
por: Tsui, Teresa C. O., et al.
Publicado: (2022)

Cost-effectiveness of adding rituximab to fludarabine and cyclophosphamide for treatment of chronic lymphocytic leukemia in Ukraine
por: Mandrik, Olena, et al.
Publicado: (2015)

Cost-effectiveness analysis of rituximab versus natalizumab in patients with relapsing remitting multiple sclerosis
por: Rezaee, Mehdi, et al.
Publicado: (2022)

Cost-effectiveness analysis of a multifactorial fall prevention intervention in older home care clients at risk for falling
por: Isaranuwatchai, Wanrudee, et al.
Publicado: (2017)

Comparative Effectiveness and Safety of Pertuzumab and Trastuzumab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy for Treatment of Metastatic Breast Cancer
por: Dai, Wei Fang, et al.
Publicado: (2022)

Adding rituximab to chemotherapy for diffuse large B-cell lymphoma patients in Indonesia: a cost utility and budget impact analysis
por: Putri, Septiara, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_6rhmm0tgruc5jghi7oft0l4g13